Delia Cabrera Debuc

Dr. Cabrera DeBuc received her Ph.D. in Applied Physics (2002) from the University of Michigan. She is a Research Associate Professor of Ophthalmology at the Bascom Palmer Eye Institute, the University of Miami Miller School of Medicine. She is a biophysicist with specific training in ocular imaging technology and image analysis. Her research group has been supported by grants from the Juvenile Diabetes Research Foundation, the National Institute of Health, the Alzheimer's Association, the National Institute on Aging, the Finker Frenkel Legacy Foundation, and the National Eye Institute. Her research interests include medical applications of ultrafast laser technology and optical imaging, focusing on the human eye, including developing and using quantitative ophthalmic imaging analyses to enhance ocular health capabilities. Specifically, she has focused her research on the early detection of diabetic retinopathy using advanced optical imaging. Besides ophthalmic-image processing research, she is also actively involved in leading ocular telehealth applications and clinical research related to novel ocular imaging biomarkers for the central nervous system's neurodegenerative diseases, such as multiple sclerosis, Parkinson's, and Alzheimer's disease. Dr. Cabrera DeBuc has presented nationally and internationally on various aspects of medical image processing and novel imaging biomarker development, emphasizing ophthalmology, data science, neuroscience, and vision science. She is also an associate editor of the IEEE Transactions on Medical Imaging, an editorial board member of Scientific Reports (Nature), a Fellow of the SPIE, and a Fulbright Scholar. She is also devoted to Artificial Intelligence applications for disease diagnosis, running a multidisciplinary lab, and collaborating extensively with national and international investigators. Besides, she is an external advisory board member of the EU-funded Marie Skłodowska-Curie Innovative Training Network, "CLARIFY – CLoud ARtificial Intelligence For pathologY. "She is also the CEO and Founder of iScreen 2 Prevent, LLC, a University of Miami's spinoff company aiming to commercialize an AI-based screening platform to predict persons at risk of AD in primary and community health care settings.